Although medicine has made great strides in the field of cancer treatment, many obstacles still remain. For instance, even if a drug has proved efficient in a lab, it may not be so in a patient. Many cancers are highly desmoplastic. Thick fibrous tissue forms around and inside the tumour, making it highly inaccessible for conventional methods of drug delivery. A possible solution to this “logistical” problem lies in biohybrid machines (BHMs).

BioMeld (full name: A Modular Framework for Designing and Producing Biohybrid Machines) is an EU-funded research project that focuses on bio-intelligent design and production of a biohybrid machine (BHM), a drug-delivery catheter, capable of accessing hard-to-reach areas of the human body.

This project is unprecedented, since it proposes a biointelligent manufacturing pipeline of BHMs that would be self-monitoring and self-controlling, which is a radically innovative approach.

More info @ https://biomeld.eu/